Skip to Content
 

VICC toll-free number 1-877-936-8422

Clinical Trials for Cyclophosphamide (CTX)

9 Open Trials

    Trial Type Protocol No. &
    Open Date
    Summary

    Treatment

    VICCBRE1706

    02/08/2018

    A Phase III Randomized Study to Investigate the Efficacy and Safety of Atezolizumab (Anti-PDL-1 Antibody) in Combination with Neoadjuvant Anthracycline/Nab-Paclitaxel-Based Chemotherapy Compared with Placebo and Chemotherapy in Patients with Primary Invasive Triple-Negative Breast Cancer

    Treatment

    VICCBMT15116

    01/03/2018

    A Phase 2 Multicenter Study Evaluating the Efficacy of KTE-C19 in Subjects with Relapsed/Refractory Mantle Cell Lymphoma (r/r MCL)

    Treatment

    VICCMD1710

    08/03/2017

    A Phase 1/2, Open-Label, Dose-Escalation, Safety, Tolerability, and Efficacy Study of Epacadostat in Combination with a PD-1 Inhibitor and Chemotherapy in Subjects with Advanced or Metastatic Solid Tumors (ECHO-207)

    Treatment

    COGAALL1331

    02/01/2016

    Risk-Stratified Randomized Phase III Testing of Blinatumomab (IND# 117467, NSC#765986) in First Relapse of Childhood B-Lymphoblastic Leukemia (B-ALL)

    Treatment

    COGAHOD1331

    07/15/2015

    A Randomized Phase III Study of Brentuximab Vedotin (SGN-35, IND #117117) for Newly Diagnosed High-Risk Classical Hodgkin Lymphoma (cHL) in Children and Adolescents

    Treatment

    VICCNCPED1414

    04/24/2014

    HLA-haploidentical Related Marrow Grafts for the Treatment of Primary Immunodeficiencies and other Nonmalignant Disorders Using Conditioning with Low-Dose Cyclophosphamide, TBI and Fludarabine; Postgrafting Immunosuppression will Consist of a Single Low Dose of Cyclophosphamide, MMF and Tacrolimus

    Treatment

    VICCNCBMT12108

    05/08/2013

    A Non-Myeloablative Conditioning and Transplantation of Partially HLA-Mismatched and HLA-Matched Bone Marrow for Patients with Sickle Cell Disease and Other Hemoglobinopathies

    Treatment

    COGAALL1131

    04/05/2012

    A Phase III Randomized Trial for Newly Diagnosed High Risk B-precursor Acute Lymphoblastic Leukemia (ALL) Testing Clofarabine (IND #73789, NSC# 606869) in the Very High Risk Stratum

    Treatment

    COGACNS0831

    05/12/2011

    Phase III Randomized Trial of Post-Radiation Chemotherapy in Patients with Newly Diagnosed Ependymoma Ages 1 to 21 years.


    Print this page for your doctor